Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma.

× No keyword cloud information.

11 in total

1. Cabergoline associated with first episode mania.

Authors: Yael T Harris; Alexander Z Harris; Jose M Deasis; Stephen J Ferrando; Nirmala Reddy; Robert C Young
Journal: Psychosomatics Date: 2012-05-31 Impact factor: 2.386

Review 2. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.

Authors: Anahid Hamidianjahromi; Nicholas A Tritos
Journal: Rev Endocr Metab Disord Date: 2022-09-20 Impact factor: 9.306

3. Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report.

Authors: Ana Carolina Correa E Castro; Andressa Alexandre de Araujo; Mariana Coelho Botelho; João Bosco Nascimento; Rafaela Marchon de Souza; Monica Roberto Gadelha; Antonio E Nardi; Alice Helena Dutra Violante
Journal: Front Psychiatry Date: 2022-05-26 Impact factor: 5.435

Review 4. Treating prolactinomas with dopamine agonists: always worth the gamble?

Authors: Sean Noronha; Victoria Stokes; Niki Karavitaki; Ashley Grossman
Journal: Endocrine Date: 2015-09-04 Impact factor: 3.633

5. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.

Authors: Maya Barake; A Eden Evins; Luke Stoeckel; Gladys N Pachas; Lisa B Nachtigall; Karen K Miller; Beverly M K Biller; Nicholas A Tritos; Anne Klibanski
Journal: Pituitary Date: 2014-04 Impact factor: 4.107

6. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.

Authors: Irina Bancos; Michael R Nannenga; J Michael Bostwick; Michael H Silber; Dana Erickson; Todd B Nippoldt
Journal: Clin Endocrinol (Oxf) Date: 2013-12-16 Impact factor: 3.478

7. Current awareness: pharmacoepidemiology and drug safety.

Authors:
Journal: Pharmacoepidemiol Drug Saf Date: 2008-06 Impact factor: 2.890

8. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.

Authors: M Zibetti; S Grottoli; G Beccuti; F Guaraldi; G Natta; V Cambria; N Prencipe; A Cicolin; E Montanaro; L Lopiano; E Ghigo
Journal: J Endocrinol Invest Date: 2020-12-12 Impact factor: 4.256

Review 9. The role of dopamine in risk taking: a specific look at Parkinson's disease and gambling.

Authors: Crystal A Clark; Alain Dagher
Journal: Front Behav Neurosci Date: 2014-05-30 Impact factor: 3.558

Review 10. Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

Authors: Anastasia P Athanasoulia-Kaspar; Kathrin H Popp; Gunter Karl Stalla
Journal: Endocr Connect Date: 2018-01-29 Impact factor: 3.335